Telix Pharmaceuticals Limited
TLXNASDAQHealthcare● Active
$9.29
$-0.01(-0.11%)
Market Cap$3.1B
P/E Ratio—
52W High$18.49
52W Low$6.28
Telix Pharmaceuticals Limited (TLX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TLX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.21B | $0.78B | $0.50B | $0.16B | $0.01B |
| Cost of Revenue | $0.57B | $0.27B | $0.19B | $0.07B | $0.04B |
| Gross Profit | $0.64B | $0.51B | $0.31B | $0.09B | $0.01B |
| Gross Margin %(computed) | 53.11% | 65.08% | 62.56% | 59.29% | 66.46% |
| Operating Expenses | |||||
| R&D Expenses | $0.26B | $0.12B | $0.13B | $0.06B | $0.03B |
| G&A Expenses | $0.00B | $0.12B | $0.08B | $0.05B | $0.04B |
| Total Operating Expenses | $0.61B | $0.43B | $0.26B | $0.19B | $0.05B |
| Operating Income | $0.03B | $0.08B | $0.02B | ($0.09B) | ($0.08B) |
| Operating Margin %(computed) | 2.21% | 10.49% | 3.15% | -57.42% | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.06B | $0.02B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | $0.06B | $0.00B | ($0.10B) | ($0.10B) |
| Income Tax Expense | $0.00B | $0.01B | ($0.00B) | $0.01B | ($0.02B) |
| Net Income | ($0.01B) | $0.05B | $0.01B | ($0.10B) | ($0.08B) |
| Net Margin %(computed) | -0.89% | 6.37% | 1.04% | -65.01% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.03 | $0.15 | $0.02 | $-0.34 | $-0.29 |
| Wtd Avg Shares | 0.34B | 0.33B | 0.32B | 0.31B | 0.28B |
| EBITDA | $0.08B | $0.10B | $0.02B | ($0.09B) | ($0.07B) |
| EBITDA Margin %(computed) | 6.62% | 12.54% | 4.57% | -57.99% | -922.50% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · AUD · B
Explore more Telix Pharmaceuticals Limited data
About Telix Pharmaceuticals Limited (TLX) Income Statement
Telix Pharmaceuticals Limited (TLX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TLX reported revenue of $1.21B, gross profit of $0.64B (gross margin 53.11%), and net income of ($0.01B) — a net profit margin of -0.89%.
Frequently asked questions
TLX · 4 questionsTelix Pharmaceuticals Limited (TLX) reported revenue of $1.21B for 2025, up 53.9% year-over-year.
TLX revenueTLX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08